tau Proteins
A. Koppara, Wolfsgruber, S., Kleineidam, L., Schmidtke, K., Frölich, L., Kurz, A., Schulz, S., Hampel, H., Heuser, I., Peters, O., Reischies, F. M., Jahn, H., Luckhaus, C., Hüll, M., Gertz, H. - J., Schröder, J., Pantel, J., Rienhoff, O., Rüther, E., Henn, F., Wiltfang, J., Maier, W., Jessen, F., Kornhuber, J., and Wagner, M.,
“The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.”,
J Alzheimers Dis, vol. 49, no. 2, pp. 547-60, 2016.
J. C. Morris, Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., and Mintun, M. A.,
“APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”,
Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R.,
“Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R.,
“Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
M. T. Fodero-Tavoletti, Okamura, N., Furumoto, S., Mulligan, R. S., Connor, A. R., McLean, C. A., Cao, D., Rigopoulos, A., Cartwright, G. A., O'Keefe, G., Gong, S., Adlard, P. A., Barnham, K. J., Rowe, C. C., Masters, C. L., Kudo, Y., Cappai, R., Yanai, K., and Villemagne, V. L.,
“18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.”,
Brain, vol. 134, no. Pt 4, pp. 1089-100, 2011.
M. T. Fodero-Tavoletti, Okamura, N., Furumoto, S., Mulligan, R. S., Connor, A. R., McLean, C. A., Cao, D., Rigopoulos, A., Cartwright, G. A., O'Keefe, G., Gong, S., Adlard, P. A., Barnham, K. J., Rowe, C. C., Masters, C. L., Kudo, Y., Cappai, R., Yanai, K., and Villemagne, V. L.,
“18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.”,
Brain, vol. 134, no. Pt 4, pp. 1089-100, 2011.
F. Piazza, Greenberg, S. M., Savoiardo, M., Gardinetti, M., Chiapparini, L., Raicher, I., Nitrini, R., Sakaguchi, H., Brioschi, M., Billo, G., Colombo, A., Lanzani, F., Piscosquito, G., Carriero, M. Rita, Giaccone, G., Tagliavini, F., Ferrarese, C., and DiFrancesco, J. C.,
“Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”,
Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
J. Spiegel, Pirraglia, E., Osorio, R. S., Glodzik, L., Li, Y., Tsui, W., Louis, L. A. Saint, Randall, C., Butler, T., Xu, J., Zinkowski, R. P., Zetterberg, H., Fortea, J., Fossati, S., Wisniewski, T., Davies, P., Blennow, K., and de Leon, M. J.,
“Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.”,
J Alzheimers Dis, vol. 49, no. 1, pp. 93-100, 2016.
J. Spiegel, Pirraglia, E., Osorio, R. S., Glodzik, L., Li, Y., Tsui, W., Louis, L. A. Saint, Randall, C., Butler, T., Xu, J., Zinkowski, R. P., Zetterberg, H., Fortea, J., Fossati, S., Wisniewski, T., Davies, P., Blennow, K., and de Leon, M. J.,
“Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.”,
J Alzheimers Dis, vol. 49, no. 1, pp. 93-100, 2016.
P. Pastor, Moreno, F., Clarimón, J., Ruiz, A., Combarros, O., Calero, M., de Munain, A. López, Bullido, M. J., de Pancorbo, M. M., Carro, E., Antonell, A., Coto, E., Ortega-Cubero, S., Hernandez, I., Tárraga, L., Boada, M., Lleo, A., Dols-Icardo, O., Kulisevsky, J., Vázquez-Higuera, J. Luis, Infante, J., Rábano, A., Fernández-Blázquez, M. Ángel, Valentí, M., Indakoetxea, B., Barandiarán, M., Gorostidi, A., Frank-García, A., Sastre, I., Lorenzo, E., Pastor, M. A., Elcoroaristizabal, X., Lennarz, M., Maier, W., Rámirez, A., Serrano-Ríos, M., Lee, S. E., and Sánchez-Juan, P.,
“MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOEɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium.”,
J Alzheimers Dis, vol. 49, no. 2, pp. 343-52, 2016.
P. Pastor, Moreno, F., Clarimón, J., Ruiz, A., Combarros, O., Calero, M., de Munain, A. López, Bullido, M. J., de Pancorbo, M. M., Carro, E., Antonell, A., Coto, E., Ortega-Cubero, S., Hernandez, I., Tárraga, L., Boada, M., Lleo, A., Dols-Icardo, O., Kulisevsky, J., Vázquez-Higuera, J. Luis, Infante, J., Rábano, A., Fernández-Blázquez, M. Ángel, Valentí, M., Indakoetxea, B., Barandiarán, M., Gorostidi, A., Frank-García, A., Sastre, I., Lorenzo, E., Pastor, M. A., Elcoroaristizabal, X., Lennarz, M., Maier, W., Rámirez, A., Serrano-Ríos, M., Lee, S. E., and Sánchez-Juan, P.,
“MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOEɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium.”,
J Alzheimers Dis, vol. 49, no. 2, pp. 343-52, 2016.
M. Carmona-Iragui, Fernández-Arcos, A., Alcolea, D., Piazza, F., Morenas-Rodriguez, E., Antón-Aguirre, S., Sala, I., Clarimón, J., Dols-Icardo, O., Camacho, V., Sampedro, F., Munuera, J., Nuñez-Marin, F., Lleo, A., Fortea, J., Gómez-Ansón, B., and Blesa, R.,
“Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”,
J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
M. Carmona-Iragui, Fernández-Arcos, A., Alcolea, D., Piazza, F., Morenas-Rodriguez, E., Antón-Aguirre, S., Sala, I., Clarimón, J., Dols-Icardo, O., Camacho, V., Sampedro, F., Munuera, J., Nuñez-Marin, F., Lleo, A., Fortea, J., Gómez-Ansón, B., and Blesa, R.,
“Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”,
J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
J. Vallortigara, Whitfield, D., Quelch, W., Alghamdi, A., Howlett, D., Hortobágyi, T., Johnson, M., Attems, J., O'Brien, J. T., Thomas, A., Ballard, C. G., Aarsland, D., and Francis, P. T.,
“Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia.”,
J Alzheimers Dis, vol. 50, no. 1, pp. 101-10, 2016.
E. Morenas-Rodriguez, Cervera-Carles, L., Vilaplana, E., Alcolea, D., Carmona-Iragui, M., Dols-Icardo, O., Ribosa-Nogué, R., Muñoz-Llahuna, L., Sala, I., M Sánchez-Saudinós, B., Blesa, R., Clarimón, J., Fortea, J., and Lleo, A.,
“Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.”,
J Alzheimers Dis, vol. 50, no. 2, pp. 539-46, 2016.
D. Renard, Wacongne, A., Ayrignac, X., Charif, M., Fourcade, G., Azakri, S., Le Floch, A., Bouly, S., Marelli, C., Arquizan, C., Hirtz, C., Gabelle, A., Thouvenot, E., and Lehmann, S.,
“Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”,
J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.
M. Frenkel-Pinter, Tal, S., Scherzer-Attali, R., Abu-Hussien, M., Alyagor, I., Eisenbaum, T., Gazit, E., and Segal, D.,
“Naphthoquinone-Tryptophan Hybrid Inhibits Aggregation of the Tau-Derived Peptide PHF6 and Reduces Neurotoxicity.”,
J Alzheimers Dis, vol. 51, no. 1, pp. 165-78, 2016.
E. Aso, Andrés-Benito, P., Carmona, M., Maldonado, R., and Ferrer, I.,
“Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”,
J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
R. A. Stern, Tripodis, Y., Baugh, C. M., Fritts, N. G., Martin, B. M., Chaisson, C., Cantu, R. C., Joyce, J. A., Shah, S., Ikezu, T., Zhang, J., Gercel-Taylor, C., and Taylor, D. D.,
“Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy.”,
J Alzheimers Dis, vol. 51, no. 4, pp. 1099-109, 2016.
N. R. Barthélemy, Gabelle, A., Hirtz, C., Fenaille, F., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Junot, C., Becher, F., and Lehmann, S.,
“Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.”,
J Alzheimers Dis, vol. 51, no. 4, pp. 1033-43, 2016.
S. L. Allison, Fagan, A. M., Morris, J. C., and Head, D.,
“Spatial Navigation in Preclinical Alzheimer's Disease.”,
J Alzheimers Dis, vol. 52, no. 1, pp. 77-90, 2016.
N. Lelental, Brandner, S., Kofanova, O., Blennow, K., Zetterberg, H., Andreasson, U., Engelborghs, S., Mroczko, B., Gabryelewicz, T., Teunissen, C., Mollenhauer, B., Parnetti, L., Chiasserini, D., Molinuevo, J. Luis, Perret-Liaudet, A., Verbeek, M. M., Andreasen, N., Brosseron, F., Bahl, J. M. C., Herukka, S. - K., Hausner, L., Frölich, L., Labonte, A., Poirier, J., Miller, A. - M., Zilka, N., Kovacech, B., Urbani, A., Suardi, S., Oliveira, C., Baldeiras, I., Dubois, B., Rot, U., Lehmann, S., Skinningsrud, A., Betsou, F., Wiltfang, J., Gkatzima, O., Winblad, B., Buchfelder, M., Kornhuber, J., and Lewczuk, P.,
“Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”,
J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
M. Ángel Ontiveros-Torres, Labra-Barrios, M. Luisa, Díaz-Cintra, S., Aguilar-Vázquez, A. Ruth, Moreno-Campuzano, S., Flores-Rodríguez, P., Luna-Herrera, C., Mena, R., Perry, G., Florán-Garduño, B., Luna-Muñoz, J., and Luna-Arias, J. Pedro,
“Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3×Tg-AD Transgenic Mouse.”,
J Alzheimers Dis, vol. 52, no. 1, pp. 243-69, 2016.
